Medirox AB Competitors

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 59 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Bio-Techne is a global life sciences company that empowers scientific discovery and advances human health. Through its industry-leading branded product portfolios, including R&D Systems™ by Bio-Techne, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, the company delivers high-quality solutions and expert support that enable scientists and clinicians to make breakthrough discoveries, develop and manufacture novel therapeutics and deliver precision diagnostics across cancer research, neuroscience, diabetes, rare diseases, and beyond. Bio-Techne®, Bio-Techne Diagnostics™, Bio-Techne Spatial ™, R&D Systems™ are trademarks or registered trademarks of Bio-Techne Corporation and affiliated entities. All other trademarks, service marks, and trade names are the property of their respective owners.

Fujirebio is a world leading in vitro diagnostics (IVD) company and innovation-driven content provider, enabling breakthrough diagnostic solutions to reach patients worldwide through science, partnership, and proven global impact. Founded in Tokyo in 1950, Fujirebio has spent more than 75 years developing pioneering biomarkers and diagnostic technologies across oncology, infectious diseases, and neurological disorders. Today, our technology plays a vital role in many of the world’s most trusted IVD tests – often reaching patients through partnerships with leading diagnostic companies operating across multiple platforms. Our open business model is built on a virtuous circle: we invest more than 15% of our base revenue in R&D to develop novel diagnostic content; we prove its value through real-world validation on our own Lumipulse® platform and through our connection with SRL, one of the world’s largest clinical laboratories; and we share proven solutions globally through our Contract Development and Manufacturing Organization (CDMO) services. Revenues from these partnerships are reinvested to fuel further innovation. We are particularly active in neurological diagnostics. Our FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test represents a significant advance in accessible blood-based Alzheimer’s disease diagnostics, and our 2022 acquisition of ADx NeuroSciences further strengthened our neurological biomarker pipeline. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc. (Tokyo Stock Exchange: TYO 4544), employing more than 1,200 people across Japan, Europe, and the Americas.